Table 1.
Characteristics and Clinical Outcomes of Patients Stratified by Type of the Tumors
| Variables | All patients (n=132) | Type of the tumors |
P-value a | ||
|---|---|---|---|---|---|
| Type I (n=75) | Type II (n=57) | ||||
| Age (years) | |||||
| Mean ± SD | 54.3±9.9 | 51.3±9.3 | 58.2±9.3 | < 0.001 | |
| ≥ 60 | 43 (32.6) | 16 (21.3) | 27 (47.4) | 0.002 | |
| < 60 | 89 (67.4) | 59 (78.7) | 30 (52.6) | ||
| Parity status | |||||
| Nulliparous | 46 (34.8) | 34 (45.3) | 12 (21.1) | 0.004 | |
| Multiparous | 86 (65.2) | 41 (54.7) | 45 (78.9) | ||
| Menopausal status | |||||
| Premenopausal | 47 (35.6) | 34 (45.3) | 13 (22.8) | 0.007 | |
| Postmenopausal | 85 (64.4) | 41 (54.7) | 44 (77.2) | ||
| Stages of disease | |||||
| Stage I | 38 (28.8) | 32 (42.7) | 6 (10.5) | < 0.001 | |
| Stage II | 14 (10.6) | 9 (12.0) | 5 (8.8) | ||
| Stage III | 61(46.2) | 28 (37.3) | 33 (57.9) | ||
| Stage IV | 19 (14.4) | 6 (8.0) | 13 (22.8) | ||
| Largest tumor size in the ovaries (cm) | |||||
| ≥ 10 | 82 (62.1) | 55 (73.3) | 27 (47.4) | 0.002 | |
| < 10 | 50 (37.9) | 20 (26.7) | 30 (52.6) | ||
| Receiving NACT | 40 (30.3) | 13 (17.3) | 27 (47.4) | <0.001 | |
| Intensity of PD-L1 expression | |||||
| 1+ | 49 (37.1) | 26 (34.7) | 23 (40.4) | 0.677 | |
| 2+ | 71 (53.8) | 41 (54.7) | 30 (52.6) | ||
| 3+ | 12 (9.1) | 8 (10.6) | 4 (7.0) | ||
| High expression (≥ 2+) | 83 (62.9) | 49 (65.3) | 34 (59.6) | 0.503 | |
| Recurrence of disease | 63 (47.7) | 30 (40.0) | 33 (57.9) | 0.041 | |
| Platinum resistance b | 20 (15.2) | 13 (17.3) | 7 (12.3) | 0.423 | |
SD, standard deviation; NACT, neoadjuvant chemotherapy; PD-L1, programmed death ligand-1; a Comparing between type I and type II tumors; b, Occurring ≤ 6 months following adjuvant platinum chemotherapy.